Zobrazeno 1 - 10
of 140
pro vyhledávání: '"Farastuk, Bozorgmehr"'
Autor:
Christian M. Heidt, Jonas R. Bohn, Róbert Stollmayer, Oyunbileg von Stackelberg, Stephan Rheinheimer, Farastuk Bozorgmehr, Karsten Senghas, Kai Schlamp, Oliver Weinheimer, Frederik L. Giesel, Hans-Ulrich Kauczor, Claus Peter Heußel, Gudula Heußel
Publikováno v:
Insights into Imaging, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Objective Investigate the feasibility of detecting early treatment-induced tumor tissue changes in patients with advanced lung adenocarcinoma using diffusion-weighted MRI-derived radiomics features. Methods This prospective observational stu
Externí odkaz:
https://doaj.org/article/19f89bb48e0448caaf739e1bfb1df82f
Autor:
Christoph A. Fink, Fabian Weykamp, Sebastian Adeberg, Farastuk Bozorgmehr, Petros Christopoulos, Kristin Lang, Laila König, Juliane Hörner-Rieber, Michael Thomas, Martin Steins, Rami A. El-Shafie, Stefan Rieken, Denise Bernhardt, Jürgen Debus
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 42, Iss , Pp 100665- (2023)
Background: Combined, platinum-based thoracic chemoradiotherapy (TCR) is the current state-of-the-art treatment for patients with limited disease (LD) small-cell lung cancer (SCLC). There is only limited data available regarding the effect of comorbi
Externí odkaz:
https://doaj.org/article/9f830e93156f4ac5b00009d11a666d5a
Autor:
Farastuk Bozorgmehr, Petros Christopoulos, Inn Chung, Jelena Cvetkovic, Manuel Feißt, Johannes Krisam, Marc A. Schneider, Claus Peter Heußel, Michael Kreuter, Daniel W. Müller, Michael Thomas, Stefan Rieken
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Recently, the combination of the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab with first-line chemotherapy has demonstrated to improve outcome for patients with advanced small cell lung cancer (SCLC), leading to approv
Externí odkaz:
https://doaj.org/article/7e030e52fb5146e9b61643c7598ec3bd
Autor:
Tanja Eichkorn, Jonathan W. Lischalk, Cedric Stüwe, Eric Tonndorf-Martini, Kai Schubert, Lisa-Antonia Dinges, Sebastian Regnery, Farastuk Bozorgmehr, Laila König, Petros Christopoulos, Juliane Hörner-Rieber, Sebastian Adeberg, Klaus Herfarth, Hauke Winter, Michael Thomas, Stefan Rieken, Jürgen Debus, Rami A. El Shafie
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
IntroductionA very narrow therapeutic window exists when delivering curative chemoradiotherapy for inoperable locally advanced non-small cell lung cancer (NSCLC), particularly when large distances exist between areas of gross disease in the thorax. I
Externí odkaz:
https://doaj.org/article/37743337ff4c4493a6bda50b5b332b61
Autor:
Farastuk Bozorgmehr, Inn Chung, Petros Christopoulos, Johannes Krisam, Marc A. Schneider, Lena Brückner, Daniel Wilhelm Mueller, Michael Thomas, Stefan Rieken
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/5127c969646443f1add3597e420188ff
Autor:
Petros Christopoulos, Farastuk Bozorgmehr, Lena Brückner, Inn Chung, Johannes Krisam, Marc A. Schneider, Albrecht Stenzinger, Regina Eickhoff, Daniel W. Mueller, Michael Thomas
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK+ non-smallcell lung cancer (NSCLC) patients to over five years. In particular, second-generation ALK TK
Externí odkaz:
https://doaj.org/article/4e6781e44b744b6b9128b4b4f1cc88df
Autor:
Nicolas Hohmann, Farastuk Bozorgmehr, Petros Christopoulos, Gerd Mikus, Antje Blank, Jürgen Burhenne, Michael Thomas, Walter E. Haefeli
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 2, Pp 487-491 (2021)
The inhibitor of anaplastic lymphoma kinase (ALK) crizotinib significantly increases survival in patients with ALK‐positive non‐small cell lung cancer (NSCLC). When evaluating crizotinib pharmacokinetics (PKs) in patients taking the standard flat
Externí odkaz:
https://doaj.org/article/c3263b190a004989afea2f5553ef2b93
Autor:
Farastuk Bozorgmehr, Inn Chung, Petros Christopoulos, Johannes Krisam, Marc A. Schneider, Lena Brückner, Daniel Wilhelm Mueller, Michael Thomas, Stefan Rieken
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background Non-small cell lung cancer is the most common cause of cancer death worldwide, highlighting the need for novel therapeutic concepts. In particular, there is still a lack of treatment strategies for the group of elderly and frail p
Externí odkaz:
https://doaj.org/article/6ee57f5784934692abfb91344ca3fbd7
Autor:
Jonas Kuon, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Albrecht Stenzinger, Miriam Blasi, Farastuk Bozorgmehr, Martin Maenz, Meinhard Kieser, Marc Schneider, Michael Thomas
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-12 (2020)
Abstract Background Elderly patients represent a major fraction of non-small cell lung cancer (NSCLC) patients in routine clinical practice, but they are still underrepresented in clinical trials. In particular, data regarding efficacy and safety in
Externí odkaz:
https://doaj.org/article/1ae670ccfeb143f6862080ce2e23e2f0
Autor:
David Fisch, Farastuk Bozorgmehr, Daniel Kazdal, Jonas Kuon, Laura V. Klotz, Rajiv Shah, Florian Eichhorn, Mark Kriegsmann, Marc A. Schneider, Thomas Muley, Albrecht Stenzinger, Helge Bischoff, Petros Christopoulos
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundLarge-cell neuroendocrine lung carcinoma (LCNEC) is a rare pulmonary neoplasm with poor prognosis and limited therapeutic options.MethodsWe retrospectively analyzed all patients with metastatic LCNEC in the records of a large German academi
Externí odkaz:
https://doaj.org/article/e1f6b634e2764da99e782889394b3710